![]() Pollack et al reported the details of the full cohort analysis of the use of the monoclonal antibody, idarucizumab, for reversal of this antithrombotic medication. Dabigatran, a direct thrombin inhibitor, was the first new oral antithrombotic to be approved by the FDA, and is now the first to have an effective antidote for reversal of its antithrombotic effects. Prothrombin complex concentrate is recommended in guidelines to reverse the effects of these agents, but this treatment has never been proven to be effective. However, one of the major drawbacks has been the inability to reverse the antithrombotic effects during a bleeding emergency, such as trauma or intracranial hemorrhage. Orally administered direct thrombin inhibitors, as well as Factor Xa inhibitors, have become important additions as anticoagulants to stroke prevention therapies in patients with atrial fibrillation. Idarucizumab for dabigatran reversal – full cohort analysis. SOURCE: Pollack CV, Reilly PA, van Ryn J, et al. Fink reports he is a retained consultant for Procter & Gamble and Pfizer. Professor and Chairman, Department of Neurology, Weill Cornell Medical College Neurologist-in-Chief, New York Presbyterian Hospitalĭr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |